Nervous Disorder TRIZ Cases

Lanthionine ketimine phosphonate derivatives stimulate autophagy via modified molecular structures.

Monoclonal antibodies bind pathological TDP-43 oligomers to suppress proteinopathy, addressing the lack of effective treatments for Alzheimer's and ALS.

Administered purified and recombinant granulins rescue lysosomal dysfunction and neurodegenerative symptoms in animal models.

Organic acid addition salts of methylphenidate resist dissolution in low pH environments, preventing dose dumping while maintaining therapeutic efficacy.

A composition of 10-hydroxy-2-decenoic acid and docosahexaenoic acid treats anxiety and inflammatory conditions.

A hybrid polypeptide links GLP-1 with exendin-4 to enhance therapeutic stability.

Intraparenchymal umbilical cord blood cells reverse chronic stroke disability beyond the acute treatment window.

A serum-free dental pulp stem cell culture supernatant promotes tissue repair through immunocompetent cell differentiation.

Engineered neural progenitor cells express DREADD receptors to enable pharmacological activation of transplanted cells.

CNS-binding monoclonal antibodies target neurons and oligodendrocytes to treat white matter disease in infants.

Modified fatty acids enhance PPAR agonist activity while reducing side effects from conventional treatments.

2-Bromo-LSD resolves limited antidepressant efficacy by treating treatment-resistant depression with minimal toxicity.

A diagnostic assay measures APP-specific CD8+ T cell levels using MHC multimers to identify subjects at risk for late-onset Alzheimer's disease.

Delaying A2a receptor antagonist administration reduces levodopa-induced dyskinesias by blocking aberrant signaling.

Combines Opipramol and Venlafaxine to activate sigma-1 receptors, increasing calcium ion influx and neurotransmitter release for treatment-resistant depression.

Selective breeding establishes low nicotine levels in cultivar AOB 176 without degrading yield or quality.

Combining NSAIDs with antihistamines inhibits opioid withdrawal symptoms through targeted pharmacological action.

Three-dimensional cultured placental stromal cells rebuild the hematopoietic microenvironment to enhance survival rates of transplanted stem cells.

Intramolecular Friedel-Crafts alkylation constructs stereodefined polycyclic compounds with quaternary centers for targeted drug development.

Boryl ether oxidative fragmentation releases cargo without generating toxic quinone methide by-products.

Recombinant AAV1 vectors deliver progranulin coding sequences to the central nervous system via intra-cisterna magna injection.

Non-cytotoxic proteases resolve the contradiction between pain relief and cytotoxic side effects by inhibiting neurotransmitter release.

Urea-based CB1 allosteric modulators improve metabolic stability and reduce psychiatric side effects.

A nicotine lozenge formulation combines high and low viscosity alkylcellulose polymers to control active ingredient release.

Mutations in amino acids 51 to 63 reduce heparan sulfate binding affinity, resolving distribution limits that restricted previous clinical trial efficacy.

Engineered antibodies modulate TIM-3 activity to enhance immune responses, resolving the lack of specific regulatory molecules for cancer therapy.

Composite acellular formulations address IL-1ra stability issues by combining soluble receptors and growth factors for sustained anti-inflammatory efficacy.

A pharmaceutical capsule shell resists oxidation of ultra-pure eicosapentaenoic acid through specific film-forming material ratios.

Wearable sensor detects oxygen saturation changes to trigger mobile alerts for emergency responders.

Trans-10-hydroxy-2-decenoic acid treats autism spectrum disorder symptoms while avoiding adverse side effects common in traditional medications.

Merges 5-HT6 receptor antagonists with acetylcholinesterase inhibitors to improve cognitive function while reducing peripheral side effects.

Hibiscus syriacus flower extract reduces corticosterone and enhances serotonin expression to treat stress-induced insomnia.

Codon optimization and specific promoters stabilize transgene expression to reduce seizure frequency while minimizing brain region damage risk.

Fusion polypeptides combine interferon fragments with interleukin domains to treat hepatitis while reducing toxicities.

Electrospun polymeric fibers deliver T3 and Ibuprofen locally to reduce secondary neurodegeneration while minimizing systemic side-effects.

Covalent anchoring moieties link therapeutic payloads to extracellular vesicles, resolving payload capacity and targeting specificity trade-offs.

Low-potency pirfenidone derivatives modulate the stress-activated protein kinase system, reducing toxicity while treating pulmonary fibrosis.

A fish roe wax and Nigella sativa oil formulation regulates dopamine and serotonin levels to treat addiction withdrawal symptoms.

Extracted bioactive factors replace complex stem cell therapies to treat tissue regeneration while reducing costs.

Salubrinal prodrug analogs decompose in plasma to release the active compound, reducing toxicity and improving solubility for treating neurological disorders.

CasX:gNA systems modify the SOD1 gene to address ALS mutations while reducing delivery complexity.

Specific THC, CBC, and CBD ratios manage neuropathic pain while minimizing opioid addiction risks.

Segmenting the extracellular domain creates a stable soluble Toso protein that binds receptors to reduce inflammation and improve disease severity scores.

A non-psychoactive cannabinoid composition treats sleeplessness, anxiety, pain, and inflammation without addictive properties.

Phenothiazine compounds inhibit TNF-alpha secretion from microglia, resolving the failure of direct Abeta aggregation targeting in human trials.

Aqueous camomile extract combined with black cumin seed oil inhibits DNA synthesis in cancer cells.

Novel benzamide compounds modulate spinal glycine receptors to control spasticity.